Company: AEMD
Filing Date: 2025-07-25
Form Type: DRS
Source: 0001683168-25-005397
Chunk: 36

Company: AETHLON MEDICAL INC
Filing Date: 2025-07-25
Form: DRS
Chunk 36
---
lon, Inc. and Hemex, Inc. such
that Bishop Equities, Inc. then owned 100% of each company. Upon completion of the transaction, Bishop Equities, Inc. was renamed Aethlon
Medical, Inc. Our executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number
is (619) 941-0360. Our website address is www.aethlonmedical.com. The information contained on, or that can be accessed through, our website
is not part of, and is not incorporated into, this prospectus, and you should not rely on any such information in making the decision
of whether to purchase our securities.

Smaller Reporting Company

We
are a “smaller reporting company” as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange
Act, and have elected to take advantage of certain of the scaled disclosure available for smaller reporting companies.

<div align='center'>The Offering</div>

| Common stock offered by the Selling Securityholders | Up to 1,550,000 shares of common stock issuable upon exercise of the Inducement Warrants.                                                 |
| Common stock offered by us                          | [__] shares.                                                                                                                              |
| Pre-funded warrants                                 | We are also                                                                                                                               
 offering to those purchasers, if any, whose purchase of common stock in the Company Offering would otherwise result in such               
 purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding common        
 stock immediately following the consummation of this offering, the opportunity, in lieu of purchasing common stock, to purchase           
 pre-funded warrants to purchase up to [__] shares of our common stock. For each pre-funded warrant we sell, the                           
 number of shares of common stock we are offering will be decreased on a one-for-one basis. The purchase price of                          
 each pre-funded warrant will equal the price per share at which the shares of common stock and accompanying warrants to                   
 purchase common stock are being sold to the public in the Company Offering, minus $0.001, and the exercise price of each pre-funded       
 warrant will be $0.001 per share of common stock.                                                                                         
 Each pre-funded warrant will be exercisable immediately upon issuance                                                                     
 and will not expire. This prospectus also relates to the offering of the shares of common stock issuable upon